Colorectal Liver Metastasis: Current Management by Alejandro Serrablo et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
9 
Colorectal Liver  
Metastasis: Current Management 
Alejandro Serrablo, Luis Tejedor, Vicente Borrego and Jesus Esarte 
Miguel Servet University Hospital 
Spain 
1. Introduction 
Colorectal cancer (CRC) is the third most frequent in men in developed countries (after lung 
and prostate tumours) and second among women (after breast cancer), with approximately 
one million new cases per year throughout the world (550,000 men and 470,000 women), 
representing 14.6% and 15.2% respectively of all malignant tumours diagnosed. The role of 
colonoscopy in the screening of this pathology is crucial. CRC affecting the intestine has a 
high rate of cure (45-50%) with radical surgery. The most frequent metastatic involvement in 
CRC, after lymph nodes invasion, is seen in the liver. 
Several studies have analyzed the pre-operative prognostic factors in patients undergoing 
liver resection for liver metastases of CRC in order to select patients for surgical treatment. 
However, intraoperative and post-operative factors have been poorly studied and that could 
report on the aggressiveness of the tumour and the curative efficacy of the surgery 
performed. The purpose of surgery is resection of all liver lesions with a tumour-free 
margin, provided R0 resection (complete resection with no microscopic residual tumour) 
may be achieved with low morbidity and mortality (Choti et al. 2002; Marin et al. 2009; 
Lordan & Karanjia 2007) without endangering the life of the patient due to either liver 
insufficiency or post-operative complications. According to most authors, it should be noted 
that surgery, however extensive it is, does not prolong survival if residual microscopic or 
gross tumour is left (Harmantas et al. 1996; Kronawitter et al. 1999). 
Since Woodington and Waugh reported the first favourable results of surgical treatment for 
CRC liver metastases (Woodington & Waugh, 1964), a disease previously considered 
incurable, to date, a 5- and 10-year survival rates of 35-58% and 20-25% respectively have 
been achieved, while survival without treatment is less than 2% (Ohlsson et al. 1998; Fong et 
al. 1999).  
The key for indicating the most adequate treatment is the study conducted by a 
multidisciplinary team (Söreide et al. 2008; Artigas et al. 2007). The difficulty for assessing 
the indication stems from the fact that the presence of extrahepatic tumour, the possibility of 
achieving a tumour-free margin and the actual number of liver metastases are frequently 
known during the laparotomy. Different studies have analyzed the traditional pre-operative 
factors predicting survival in order to select patients in whom unnecessary surgery could be 
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avoided. These were factors related to the patient, the primary tumour and the liver 
metastases (Fong et al. 1999; Nordlinger et al. 1996). However, some authors do not 
contraindicate surgery in patients with poor prognostic criteria provided a R0 resection may 
be obtained, as a number of prognostic factors are known only after resection (Marín et al. 
2009). These factors include the histological study (number, resection margin size, 
microsatellites, type of growth, presence of tumour pseudocapsule, tumour differentiation 
grade, histological type, nuclear grade and number of mitoses/mm2) and the 
immunohistochemical study of the resected specimen. The latter may combine the markers 
of cell proliferation and cell cycle control, p53 and Ki67. There is increasing evidence 
supporting the concept that in human cancer, a minority of cells (tumour stem cells) has 
acquired characteristics of uncontrolled growth and the ability to form metastases (Reya et 
al. 2001; Dalerba et al. 2007; Jordan et al. 2006). This hypothesis is supported by different 
experimental observations made initially in acute myeloid leukaemia (Bonnet D & Dick J 
1997) and subsequently in human solid tumours, such as breast (Al-Hajj 2003), brain (Singh 
et al. 2004; Galli et al. 2004), colorectal (O' Brien et al. 2004; Ricci-Vitiani et al. 2007), head 
and neck (Prince et al. 2007) and pancreatic cancer (Li et al. 2007). However, this concept 
continues to be highly controversial and data reported on colorectal cancer are not yet 
conclusive (Ricci-Vitiani et al. 2007; Hill 2006).  
It is therefore interesting to know both the qualitative and quantitative stem cell population 
in the tumour using markers, such as CD44, CD133, and CD166. The tissue microarray 
(TMA) technique allows for monitoring and simultaneous evaluation of a great number of 
samples or tumour series in a single experiment, ensuring homogeneity of the techniques 
between specimens and validation of the results obtained with various histological, 
immunohistochemical and in-situ hybridization (FISH) techniques (Battifora 1986; Kononen 
et al 1998; Milanes-Yearsley et al 2002). 
In addition, over the last decade, a revolution in the approach to CRC liver metastases has 
occurred. Firstly, there was the advent of new chemotherapy drugs that have allowed better 
control of the disease, higher response rates and longer survival rates. Secondly, this has 
opened up a greater possibility of surgical rescue in more patients. Aggressive surgical 
management is called extreme liver surgery: ante-situ, in-situ and ex-situ liver resections are 
included (Mehrabi et al. 2011; Hoti et al. 2011; Oldhafer et al. 2001). 
2. Current diagnostic tools 
Imaging of the liver of CRC patients requires high sensitivity and reliable characterization of 
the lesions, allowing differentiation of malignant from benign tumours. Accurate and timely 
detection of hepatic metastases has long-range therapeutic and prognostic implications, 
since untreated liver metastases have a poor prognosis (5-year survival rate of 0–3%) while 
the resection with curative intent offers a much better one (5-year survival rate from 35% to 
58%) (El Khodary et al. 2011). An understanding of the segmental anatomy of the liver is 
imperative for localization and appropriate management of hepatic neoplasms. The 
classification proposed by Couinaud (Couinaud 1957 ) and later modified by Bismuth 
(Bismuth 1982) provides the surgically relevant information and is easily applicable to cross-
sectional imaging techniques, such as computed tomography (CT), magnetic resonance 
imaging (MRI) and ultrasonography (US).  
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The imaging assessment of potentially resectable CRC liver metastases, needed for a careful 
pre-operative selection of patients, should address the following five critical issues:  
1. Evaluation of possible liver metastases. Number, size and segmental location of 
tumours must be determined, as well as their differential diagnosis with benign lesions.  
2. Possible hilar lymph node involvement. As they represent metastases from the liver 
metastases, this lymphatic involvement carries a poor prognosis (survival rates after 
resection are 3-12%), although the pre-operative diagnosis is difficult.  
3. Vascular invasion. Obviously, assessment of vascular invasion is critical when deciding 
the appropriate surgical strategy.  
4. Liver volumetry. Measuring the volume of the future remnant liver when considering 
extended resections is recommended, since insufficient residual volume of liver 
parenchyma is a contraindication to surgery.  
5. Presence of extrahepatic disease. Although peritoneal carcinomatosis may be very 
difficult to detect, other extrahepatic involvement is usually diagnosed pre-operatively 
(Valls et al. 2009).  
Imaging techniques used nowadays for diagnosis of these lesions include US, multi-detector 
CT (MDCT), MRI and fluorine-18-fluorodeoxyglucose positron emission tomography (FDG 
PET). FDG PET and CT can be combined in order to provide fused images, allowing high 
spatial resolution and functional information in the same examination (FDG PET/CT). In 
studies with specificity higher than 85%, the sensitivity for detection of liver metastases is 
progressively increasing from US to CT, MRI and FDG PET (Kinkel et al. 2002). The 
extensive literature regarding the benefits and constraints of each of these modalities for 
detecting liver metastases shows several limitations: inadequate definition of inclusion and 
exclusion criteria, incomplete reporting of methods, lack of uniform references, etc. The best 
standard of reference is laparotomy with bimanual palpation and intraoperative 
ultrasonography (IOUS), but this was used in only a few studies (Valls et al 2001). When a 
suboptimal standard is used, underreporting of lesions and overestimation of detection rate 
are the results (van Erkel et al 2002). Another confounding factor is the different methods for 
reporting sensitivity: per patient (detection of at least one lesion per patient) and per lesion 
(detection of all lesions per patient). Therefore, it is important to inquire into the results of 
the current studies, also because improving technology can make results of prior studies 
superfluous (Lucey et al. 2006).  
2.1 Ultrasonography 
US is a rapid and non-invasive method for screening patients with suspected liver 
metastases but, although it is highly efficient in distinguishing patients with diffuse hepatic 
metastases that involve all the liver, it is more operator dependent than other imaging 
methods, fails to show parts of the liver in certain patients and its sensitivity (50-70%) and 
specificity are surpassed by other imaging studies.  
The detection of hepatic metastases is substantially improved by contrast-enhanced US 
(CEUS) compared to conventional B-mode sonography, increasing the sensitivity per lesion 
from 71% to 87% (Oldenburg & Albrecht 2008). US contrast agents consist of microbubbles 
of gas that flood the blood pool after intravenous injection and are confined to the vascular 
compartment. These agents are safe, well tolerated and have very few contraindications. 
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Metastases behave characteristically in three phases: arterial, portal venous and delayed (El 
Khodary et al. 2011). CEUS sensitivity and specificity in staging liver metastases (80–95% 
and 84–98%, respectively) approach those of CT and MRI. In addition, CEUS is useful to 
improve the detection rate of metastases smaller than 1 cm or of those lesions that are 
isoechoic with respect to adjacent liver parenchyma, thus improving the performance of 
sonography in around 13.7% of the cases (Chami et al. 2008).  
In general, if an examination of the liver by US is insufficient, then examination by CEUS 
will also be insufficient. CEUS has limited ability to observe certain parts of the liver, 
especially in obese patients and/or in cases of steatosis and it is not possible to 
simultaneously examine multiple lesions in the arterial and early portal phases. 
Hypervascular metastases and haemangiomas on one hand and metastases and small cysts 
on the other can be difficult to differentiate (Larsen 2010).  
Intraoperative diagnosis is based on IOUS and on diagnostic laparoscopy. IOUS has higher 
sensitivity than transabdominal US, MDCT and MRI, and allows identification of metastases 
0.5 cm in size and defining the relationship between lesion, vessels and biliary structures. 
With a sensitivity of 98% and a specificity of 95%, IOUS is generally considered the gold 
standard for detecting liver lesions and is regarded as a routine investigation, modifying the 
planned surgical intervention in 18-30% of the patients. In addition, Doppler and spectral 
Doppler facilitate the technique of surgical resection. Laparoscopy, which is not routinely 
used in the pre-operative evaluation of the advanced disease, allows an assessment of the 
peritoneal and pelvic spread of the primitive cancer and, with the combined use of 
laparoscopic ultrasound (LIOUS), enables detection of small metastases, varying the initial 
surgical plan in 20–30% of the cases (Guglielmi et al. 2005). Contrast enhanced IOUS (CE-
IOUS) shows some benefit over pre-operative imaging and IOUS since it seems to improve 
the ability to characterize already detected lesions and facilitate the detection of new 
metastatic lesions (Fioole et al. 2008; Leen et al. 2006; Nakano et al. 2008; Torzilli et al. 2005).  
2.2 Computed Tomography 
MDCT has a sensitivity of 70–85% and a specificity of 90%, especially for lesions bigger than 
1.5–2 cm. Sensitivity is lower for small subglissonian metastases, even though multi-slice CT 
allows identification of hepatic lesions of 0.5 cm in size (Guglielmi et al. 2005). Fast data 
acquisition and breath-hold scanning allows imaging of the liver twice. This bi-phasic 
contrast-enhanced scan during the arterial-dominant phase and the portal-venous perfusion 
phase after bolus-like contrast administration, prior to the equilibrium phase, is accepted as 
standard for the optimised display of the complex vascularization of the liver and potential 
hepatic lesions. Slice thicknesses of 2 or 4 mm are the most effective for detection of focal 
liver lesions, with an identical detection rate of 96% for both. 3-D data sets can be produced 
improving multiplanar imaging, which allows evaluation of subcapsular lesions, 
demonstration of vascular anatomy and better characterisation of the lesions. Together with 
improvements in bolus-tracking, MDCT scanning during the various vascular contrast and 
equilibrium phases allows performing CT-angiography of the liver and mesenteric vessels, 
which can be important in patients undergoing hepatic resection or transarterial chemo or 
radio-embolisation. MDCT portal venogram is useful in evaluation of the portal system. 
Additionally, quantitative perfusion studies can also be done. Thus, MDCT can be used for 
evaluating the liver lesion, liver parenchyma and hepatic vessels in the same sitting. 
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It is important to take account of the time elapsed between the radiological study and the 
operation. One recent study showed that the utility of MDCT as a pre-operative tool to 
evaluate CRC liver metastases is inversely proportional to the time interval between 
imaging and surgery, which may explain conflicting reports of the accuracy of MDCT in the 
literature (Yang et al. 2010).  
Hepatic volumetry, necessary to evaluate the feasibility of major hepatectomies, especially 
in the case of atypical resections, is provided by MDCT software able to highlight different 
liver segments and to create vascular maps for arterial and portal afferences, and for hepatic 
vein drainage. The volume of each single segment can be calculated and a simulation of 
surgical resection can be performed. Information can be displayed using coloured maps or 
three-dimensional movies (Laghi et al. 2005).  
2.3 Magnetic Resonance Imaging 
MDCT is usually preferred because it is more widely available and because it is a well-
established technique for surveying the extrahepatic abdominal organs and tissues. 
However, MRI has an advantage in the characterization of focal lesions and is also preferred 
for patients who cannot receive intravenous iodinated contrast material or when concerns 
about the risk of radiation from repeated exposure to CT, as in children or young adults, 
exists. In general, MRI sensitivity varies from 85-90% and its specificity is up to 95%, 
although a comparison of the performance of MDCT vs. MRI needs to be reassessed 
periodically, considering the rapid evolution of both technologies and the increase in 
therapeutic options available.  
Contrast media are of two types: the extracellular agents (gadolinium chelates) and the liver 
specific agents. Gadolinium is used for lesion detection and characterisation while liver 
specific agents are used as functional agents. The most commonly used substance in contrast-
enhanced dynamic MRI is extracellular gadolinium-chelate complex, which provides the 
greatest diagnostic sensitivity and specificity rates among cross-sectional techniques currently 
in use. The current standard MRI liver protocol includes a T2-weighted sequence, a T1-
weighted sequence and a three-phase technique after administration of gadolinium (arterial-
dominant, portal venous and hepatic venous or interstitial). Like CT, the detection of CRC 
liver metastases using MRI is maximized during the portal venous phase.  
The administration of organ-specific contrast agents with hepatocyte specificity 
(mangafodipir trisodium [MnDPDP], gadobenate dimeglumine [Gd-BOPTA]) or 
reticuloendothelial system specificity (superparamagnetic iron oxide [SPIO] particles, 
captured by Kupffer cells) allows an increase in the sensitivity and specificity of the method 
(Bluemke et al. 2000; Vidiri et al. 2004), but data about their benefits are controversial. 
Furthermore, these agents are generally costly and not widely available. 
Diffusion-weighted MR imaging (DWI) is a recently introduced technique to depict 
differences in molecular diffusion caused by the random motion of molecules. It provides 
excellent tissue contrast based on molecular diffusion, which is different from ordinary T1- 
and T2-weighted images, without the need for a contrast agent (El Khodary et al. 2011). An 
additional benefit of DWI is the ability to derive quantitative indices, which may be 
important in the assessment of disease response to novel therapeutics, including anti-
vascular and anti-angiogenic therapy, since conventional assessment based on measuring 
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lesion size is insensitive to early, treatment-related changes (Koh et al. 2006). In summary, 
DWI is a simple and sensitive method for screening focal hepatic lesions and is useful for 
differential diagnosis (Koike et al. 2009).  
2.4 Positron Emission Tomography 
FDG PET is a highly sensitive and specific imaging study detecting hepatic metastases from 
CRC (92–100% and 85–100% respectively), although for some authors the strength of these 
data is moderate (Lucey et al. 2006). Several studies have also shown the utility of FDG PET 
in identifying additional metastatic lesions when initial CT showed single hepatic 
metastases and, thus, changed the management strategy. Nevertheless, false negative and 
false positive findings in FDG PET for hepatic metastases are not negligible (Udayasankar et 
al. 2008) and its positive predictive value (PPV) is not high, leading to some authors to 
confirm histologically the FDG PET findings suggesting non-resectability (Valls et al. 2009).  
Two meta-analyses have demonstrated high diagnostic values of PET in the evaluation of 
hepatic metastases (Bipat et al. 2005; Wiering et al. 2005), as well as a recent review (Patel et 
al. 2011) confirming the superior sensitivity of FDG PET for detecting liver metastases on a 
per patient basis, but not on a per lesion basis. Other papers have shown FDG PET/CT to be 
slightly less sensitive than MRI with liver-specific contrast agents or dedicated sequences for 
small lesions (Coenegrachts et al. 2009), but more sensitive than MDCT alone (Kong et al. 
2008; Selzner et al. 2004), although its role is not yet clear owing to the small number of 
studies (Niekel et al. 2010). In the context of CRC metastases, the role of FDG PET/CT is to 
avoid unnecessary surgery, based on its ability to detect extrahepatic foci of disease (nodal 
metastases, lung nodules) that are not depicted or characterized as malignant by other 
imaging methods (Sørensen et al. 2007). In addition, this technology is not suitable for liver 
resection planning. In patients evaluated with FDG PET prior to surgery, a lower risk of 
“non-therapeutic laparotomy” (Pawlik et al. 2009) and improved survival (Fernandez et al. 
2004) has been observed, reflecting better patient selection.  
A recent meta-analysis reviewing more than 3,000 patients found that sensitivity of CT, MR 
imaging and FDG PET on a per lesion basis were 74.4%, 80.3% and 81.4%, respectively, 
while on a per patient basis, the sensitivities were 83.6%, 88.2% and 94.1%, respectively. 
Specificity estimates were comparable. No differences were seen for lesions measuring at 
least 10 mm. Data about FDG PET/CT were too limited for comparisons with other 
modalities (Niekel et al. 2010).  
In brief, although every modality has benefited from advances in technology, MDCT 
scanning remains a dominant imaging modality not only for lesion detection and pre-
operative planning, but also for treatment monitoring and post-treatment surveillance. 
High-resolution CT with contrast combined with FDG PET/CT may obviate the need for 
additional studies and may improve patient management (Bipat et al. 2007; Doan et al. 2010; 
Vauthey 2006). Dynamic gadolinium-based contrast-enhanced MRI should be reserved for 
problem solving. MRI has the highest sensitivity for lesion detection, but because of its low 
sensitivity in detecting extrahepatic disease in the peritoneum and chest, it is not a desirable 
primary imaging modality (Vauthey 2006) except for evaluating patients who have not 
previously undergone therapy (Lucey et al. 2006; Niekel et al. 2010). Ultimately, the 
modality used must be tailored not only to the patient and the clinical situation, but also to 
the imaging expertise within the institution.  
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3. Current criteria for resectability 
Improvements in pre-operative imaging techniques, patient selection and surgical 
techniques, as well as the introduction of new cytotoxic and biologic agents for pre-
operative and post-operative chemotherapy have improved the resectability rate and almost 
doubled the 5-year survival rate for patients with CRC liver metastases, from about 30% two 
decades ago to nearly 60%. In this setting, with the care of these patients rapidly evolving, 
the standards of care needed to be redefined. The criteria for resectability of these 
metastases have changed dramatically. Features such as the number of lesions (1 to 3 
unilobar metastases), the size of the lesion (less than 5 cm), preferably presenting at least 12 
months after resection of the primary tumour, resectable with a minimum margin of 1 cm in 
width and without hilar adenopathy or extrahepatic disease, are no longer considered as 
determinant factors regarding resectability and, thereby, are invalid to deny a patient the 
opportunity of lengthy survival.  
Regarding the number of metastasis, Altendorf-Hofmann did not find long-term differences 
in the survival rates between patients with 1 to 3 metastasis and those with 4 or more, if a R0 
resection had been obtained (Altendorf-Hofmann et al. 2003). Moreover, some studies have 
shown that the degree of response to chemotherapy is a stronger predictor factor for long-
term survival than the number of metastasis. Regarding tumour size and prognosis, reports 
have been conflicting. Evidence shows that size is not a resectability factor, but a factor 
related to tumour aggressiveness. 
It has been shown that the actual width of the surgical margin has no effect on survival as 
long as the margin is microscopically negative (Figueras et al. 2007; Lordan 2007; Pawlik et 
al. 2005). A margin greater than 10mm is considered to be optimum, although this has 
changed too (Casanova et al. 2004). Although surgeons should continue to plan hepatic 
resection to preserve a "safety zone" and should avoid routine use of "minimum margin" 
surgery, a predicted margin of less than 1 cm should no longer be considered an exclusion 
criterion for resection.  
Historically, extrahepatic disease has been almost universally accepted as a 
contraindication to liver resection. Recently, however, some series have shown a 5-year 
survival rate of 12% to 37% after liver resection in selected patients with extrahepatic 
disease, independent of the location of that disease (lung, primary colorectal recurrence, 
retroperitoneal or hepatic pedicle lymph nodes, peritoneal carcinomatosis, miscellaneous) 
(Elias et al. 2003, 2005). In most cases, incidental peritoneal disease found at laparotomy 
would contraindicate hepatic resection. In general, resection in such patients should only 
be considered after documentation of stable/responsive disease with systemic 
chemotherapy and when an R0 resection of both intrahepatic and extrahepatic disease is 
feasible. From an anatomic and prognostic perspective, it seems appropriate to 
recommend that patients with combined liver and extrahepatic disease be reported 
separately from those meeting the traditional resectable criteria, and be designated as 
borderline resectable (Vauthey 2007).  
Positive hilar lymph nodes are associated with a poor outcome and have been traditionally 
considered as a contraindication to hepatic resection of CRC liver disease. Recent papers 
have reported long-term survival in some patients with hilar nodal metastases and have 
concluded that this patient population may still benefit from hepatic resection and 
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lymphadenectomy, provided that involved nodes are in the hepatoduodenal-retropancreatic 
area and not in the common hepatic artery/celiac-axis region (Adam et al. 2008; Jaeck 2003). 
Although patients with microscopic involvement may derive a benefit from hepatic 
resection, gross involvement of the hilar nodes should be considered a relative 
contraindication to resection. 
At present, the criteria for resectability include any patient in whom all disease can be 
removed with a negative margin and who has adequate hepatic reserve. That is to say, 
instead of resectability being defined by what is removed, now it is sustained by what will 
remain after resection, including patients with extrahepatic disease (Pawlik et al. 2008). 
Interestingly, none of the traditional adverse prognostic indicators of recurrence, such as 
carcinoembryonic antigen more than 200 ng/mL, short disease-free interval, node-positive 
primary, tumour size more than 5 cm, multiple tumours, or synchronous presentation, 
precluded long-term survival, except for a positive resection margin (Vauthey 2007).  
In 2006, the Consensus Conference on Colorectal Liver Metastases of the American Hepato-
Pancreato-Biliary Association (AHPBA) established that CRC liver metastases should be 
defined as resectable when the disease can be completely resected, two adjacent liver 
segments can be spared with an adequate vascular inflow and outflow and biliary drainage, 
and the volume of the liver remaining after resection (future liver remnant [FLR]) will be 
adequate (at least 20% of the total estimated liver volume for normal parenchyma, 30–60% if 
the liver is injured by chemotherapy, steatosis or hepatitis, or 40–70% in the presence of 
cirrhosis, depending on the degree of underlying hepatic dysfunction) (Vauthey 2006). 
When hepatic metastatic disease is not optimally resectable based on insufficient remnant 
liver volume, pre-operative chemotherapy, portal vein embolization or staged liver resection 
can be considered. Also, ablative techniques may be considered alone or in conjunction with 
resection. All original sites of disease need to be amenable to ablation or resection (Abdalla 
et al. 2006; Adam et al. 2006; Donadon et al. 2007; Garden et al. 2006).  
Resection should be offered to all patients who are suitable candidates and neoadjuvant 
chemotherapy should be considered in patients who are deemed unresectable at initial 
evaluation (Doan et al. 2010). Novel chemotherapeutic regimens combining 5-FU, folinic 
acid and oxaliplatin and/or irinotecan have been associated with improved response rates 
(approximately 50%), allowing 10-30% of the patients with initially unresectable disease 
to be successfully treated with liver surgery (Adam et al. 2004). In addition, combination 
with biologic agents that target angiogenesis and the epidermal growth factor receptor 
(EGFR), bevacizumab and cetuximab, achieves response rates of up to 70%, increasing 
these figures (Vauthey 2006). Re-evaluation for resection should be done after 2 or 3 
months of pre-operative chemotherapy and every 2 months thereafter. Tumour 
progression before surgery is associated with a poor outcome, even after potentially 
curative hepatectomy. Tumour control before surgery is crucial to offer a chance of 
prolonged remission in patients with multiple metastases (Adam et al. 2004). Patients 
should be referred early for evaluation for resection. The peri-operative complication rate, 
including hepatobiliary complications, is higher with lengthy pre-operative chemotherapy 
and is likely related to the prolonged and sequential use of multiple regimens (de Haas et 
al. 2011).  
Once patients have been diagnosed and a decision made in a multidisciplinary setting that 
resection is appropriate, it is essential to ensure that patients undergo repeat high quality 
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abdominopelvic CT (or MRI) within a month of the date of surgery. Chest CT should also be 
performed at this time.  
4. Chemotherapy and surgery 
The high recurrence rate and the overall poor “true” survival after surgical resection of CRC 
liver metastases led to the incorporation of the use of chemotherapy. This treatment can be 
administered in different strategies: neoadjuvant, peri-operative, adjuvant and conversion 
or downstaging. The latter is administrated to patients with unresectable disease with the 
goal of downsizing the tumour, re-staging it and re-considering its resection.  
Chemotherapy seems to improve outcomes compared with surgery alone. Current 
chemotherapeutic regimens lead to improved survival in patients with unresectable liver 
metastases. Resection of the primary tumour and the liver lesions is the optimal 
management of stage IV CRC with liver metastases. For patients with extensive liver 
metastases, FOLFOX (folinic acid, 5-fluorouracil and oxaliplatin) and FOLFIRI (irinotecan 
instead of oxaliplatin) have improved resection rates and survival. Upfront chemotherapy in 
the asymptomatic patient compared with resection of the primary tumour does not appear 
to affect survival significantly. However, given that 60% of the patients were alive after 2 
years, resection of the primary lesion for palliative reasons and local control must be 
considered in rectal cancer (Cellini et al. 2010). 
Optimal regimens and sequencing of chemotherapies when liver resection is an option are 
unclear. Some suggest that treatment of resectable liver metastases, in the absence of high-
risk features (Fong score) should begin with surgery and consider adjuvant chemotherapy 
after surgery (Fong et al. 1999). If high-risk features are present, most physicians prefer a 
short course of systemic pre-operative chemotherapy. Peri-operative therapy and regional 
therapy with hepatic arterial infusion (HAI) increase disease-free survival (DFS) when 
compared with surgery alone. In unresectable disease, systemic chemotherapy with or 
without a biologic agent or HAI with systemic therapy must be considered. If the disease 
becomes resectable, adjuvant treatment should follow surgery. Adjuvant chemotherapy is 
usually FOLFOX, but HAI combined with systemic chemotherapy is also an option. The role 
of adjuvant treatment after liver resection should not be viewed in isolation, but rather in 
the context of prior treatment, surgical preference and individual patient characteristics. 
Conducting randomized trials examining the role of adjuvant chemotherapy has been 
difficult because of the rapidly changing chemotherapy regimens and drugs (Power & 
Kemeny 2010). 
Operated patients with a perforated tumour or a considerable lymphatic burden are 
considered candidates for neoadjuvant chemotherapy before liver surgery, followed by a re-
evaluation after 3 months (Garden et al. 2009). The algorithm of the treatment may be that 
shown in Figure 1 (Kopetz & Vauthey 2008). 
During the treatment with 5-fluorouracil/folinic acid plus oxaliplatin or 5-
fluorouracil/folinic acid plus irinotecan, the patients deemed to be resectable should be 
considered as surgical candidates regardless of the associated adverse predictive factors. 
The emergence of EGFR antibody agents, which act effectively in patients with K-ras wild-
type tumour, fosters treatment individualization (Shimada et al. 2009). 
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Fig. 1. *Pre-operative therapy depends on the multidisciplinary team and the analyses of the 
individual case. In some cases, the first option can be resection without pre-operative 
chemotherapy. **Portal vein embolization (PVE) can be associated to these approaches 
according to future liver remnants (FLR) volume and the status of the liver (normal, 
postchemotherapy and cirrhotic). 
The efficacy of the peri-operative chemotherapy on survival benefit for resectable liver 
metastases has not been justified. However, the timing and the indication of the surgery are 
dramatically changing with the development of chemotherapeutic agents. The 
overwhelming majority of patients with resectable metastases receive some sort of 
chemotherapy, although it is not known if the adjuvant regimen is better than the 
neoadjuvant. The EORTC 40983 study did not demonstrate a clear advantage of pre-
operative chemotherapy in patients with initially resectable metastasis, but it could not 
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answer either if neoadjuvant, adjuvant or peri-operative chemotherapy is superior. 
Detractors claim that chemotherapy delays surgery while supporters point out that surgery 
is facilitated and that the treatment provides information on tumour biology (Nordlinger et 
al. 2008). The surgeon’s main concern is to operate on patients with livers affected by 
chemotherapy, which are usually more rigid, more difficult to manage and tend to bleed 
more easily. The same study demonstrated that no patient progressed from a resectable 
disease to an unresectable one, that short cycles of treatment provided minimal liver 
toxicity, that morbidity was similar in both groups and that survival improved in the 
chemotherapy sub-group. However, the problem persists over the timing of administering 
chemotherapy and the management of “ghost lesions” after complete response that cannot 
be detected with IOUS.  
5. Rescuing more patients 
In 1986, Ekberg provided several contraindications for the surgery of liver metastases of 
colorectal origin (4 or more nodules, a size greater than 5 cm, presence of extrahepatic 
disease and the inability to resect with a margin greater than 1 cm). Others studies 
corroborated these findings. A thorough analysis of these papers could have reduced their 
influence realising that they had short series or that their statistical analysis was 
univariate. As previously stated, these criteria are deemed obsolete. So the question is: can 
all disease be resected while leaving a functional liver remnant? (Charnsangavej et al. 
2006). There exist some innovative strategies that increase the volume of the hepatic 
remnant. Portal vein embolization (PVE) or ligation causes atrophy of the ipsilateral 
hemiliver and hypertrophy of the contralateral side. PVE appears to be particularly 
valuable in patients who present with underlying liver disease. The concomitant 
administration of chemotherapy may decrease both the tumour load and post-operative 
recurrences. Furthermore, aggressive approaches in selected cases can provide the only 
possible cure.  
5.1 Downstaging chemotherapy 
Downstaging chemotherapy is indicated for metastatic disease and for syncronicity in 
nonresectable disease. Intravenous or HAI downstaging chemotherapy showed a 
resectability of 20% (Fusai & Dadvison 2003). The advent of oxaliplatin and irinotecan 
reached response rates of up to 50% increased over 65% with the addition of bevazucimab 
and cetuximab. Although there are no reports of outcomes of liver resection after HAI, its 
complication rates are so high (57%) that it is dismissed as a first option.  
When treating these patients, the question arises as to whether to continue treatment until 
reaching the maximal effect or stopping once the disease becomes resectable. In general, pre-
operative chemotherapy should be stopped once the intrahepatic disease has been 
downsized to the point where hepatic resection is feasible. Surgery should be considered 
after 3 or 4 cycles in order to reduce liver toxicity, and therefore surgical morbidity, and to 
avoid a complete clinical response, difficult to trace intraoperatively. In most patients 
receiving chemotherapy, a complete response on CT scan does not mean cure (Benoist et al. 
2006) due to the fact that in over 80% of the cases there are viable cancer cells in the initial 
site of the metastasis. Current management of these ghost lesions is to remove all of them if 
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possible, considering the future liver remnant. In general, all the original sites of disease 
noted on the pre-therapy imaging need to be resected or ablated. 
Since post-operative morbidity affects long-term survival (Laurent et al. 2003), length of 
chemotherapy treatment must be taken into account. In recent years more and more 
patients with stable long-term disease (more than 20 months) are considered for surgical 
treatment. Irinotecan and oxaliplatin have been associated with the development of 
steatohepatitis. Among patients receiving these drugs, the rates of complications and 
death after major liver resection are likely to be higher compared to patients not receiving 
chemotherapy, although this is not completely clear. Albeit systemic treatment is very 
effective in reducing tumour burden and facilitates the surgical therapy in previously 
unresectable patients, the recurrence rate is high because of the presence of residual 
microscopic disease. 
5.2 Portal vein embolization 
Based on objective date, consensus has been reached on what is an adequate liver remnant 
and what are the “safe” resection percentages depending on the quality and health of the 
liver (Zorzi et al. 2007). Figure 2.  
 
 
 
 
 
 
Fig. 2. Minimum FLR volume needed for safe liver resection in patients with normal, 
intermediate disease or cirrhotic liver (Zorzi et al. 2007). 
When the future liver remnant (FLR) is insufficient PVE should be considered. PVE also 
constitutes a dynamic pre-operative test on the capacity of the liver to respond to the 
surgical aggression. If a hypertrophy greater than 5% is achieved after PVE, there is a low 
risk of a terrible post-operative liver insufficiency (Ribero et al. 2007). Chemotherapy does 
not seem to affect the hypertrophy induced by PVE. A few studies using bevazucimab 
recommend a 6 week waiting period between the last dose and the hepatectomy, although 
its influence on the hypertrophy is unclear.   
Future Liver Remnant 
Normal Liver >20% 
Liver injury >30% 
Cirrhosis >40% 
If < then 
PVE should 
consider 
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PVE is well tolerated with minimum side effects such as fever, nausea, and transient 
abnormality of liver function test. The complication rate is below 5% (Abdallah et al. 2001). 
Azoulay et al. reported that PVE increased the feasibility of liver resection by 19% and that 
the actuarial survival rate was 40% at 5 years, similar to that of patients resected without 
PVE (Azoulay et al. 2000). 
5.3 Two-stage hepatectomy 
Two-stage hepatectomy is one of the methods to increase the resectability of liver tumours. 
Its objective is to eliminate the entire tumour burden. The first stage can also be performed 
together with laparoscopic colorectal resection. It consists of combining two sequential and 
planned liver resections when it is impossible to resect all liver metastases in a single 
procedure, while preserving at least 30% of functional liver volume to avoid post-operative 
liver failure. Frequently, it is associated with peri-operative systemic chemotherapy and 
PVE, although it is not a rule (Jaeck et al. 2004) (Figure 3). 
The first hepatectomy attempts to resect the majority of liver tumours and to get 
hypertrophy of the remnant liver with or without PVE. The second hepatectomy is 
performed at least 4 weeks later to allow time for growth and hypertrophy of the FLR. The 
design of the technique must be meticulous well in advance of the first resection as an 
important strategy to achieve complete removal, admitting that around 30% of patients will 
not be rescued on the second hepatectomy.  
Usually, on the first hepatectomy the future remnant liver is cleared out of tumours with 
non-anatomic resections and/or radiofrequency ablation or at most a single segment 
resection. As mentioned, it can be associated to the removal of the primary colorectal 
tumour, preferably through a laparoscopic approach or using a “J” incision if it is located on 
the right colon. After 2 to 4 weeks after the clearance of the FRL, percutaneous PVE is 
performed. Alternatively, PVE can be done during the first hepatectomy through the 
ligation and alcoholization of the right portal vein, which is the side more often embolized. 
The second hepatectomy can be done on the fourth of fifth week after PVE, when an 
adequate hypertrophy of the non-embolized hemi-liver is achieved.  
Some authors recommend pre-operative chemotherapy during the entire process. This 
should be determined by the criteria of the multidisciplinary team according to each 
individual case (Adam et al. 2000). We carry out this procedure by performing PVE in the 
first hepatectomy with or without the removal of the primary tumour. After a 4 week 
waiting period and a CT confirming an adequate FRL, a second hepatectomy is performed. 
If during the second stage hepatectomy new liver metastases or extrahepatic lesions are 
discovered, such as localized peritoneum implants, the procedure can still be performed if a 
R0 resection can be achieved. A recent series reports a 5 year overall survival rate of 32% for 
patients on whom the procedure had been completed (Narita et al. 2011). 
Two factors affect the success of two-stage hepatectomy: patient selection and optimal 
chemotherapy regimen. This procedure may be the only therapy able to provide long-term 
survival and a possible cure for patients with initially unresectable multiple and bilobar 
CRC liver metastases.  
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Fig. 3. Multiple and bilobar metastases, right hydronephrosis and rectum cancer involving the 
right ovarium in a 37 year old woman. After chemotherapy treatment, first stage surgery 
consisted of tumour clearance of the left liver, anterior colorectal resection, right oophorectomy 
and right PVE (lower pictures). Five weeks later an extended right hepatectomy was performed.  
5.4 Synchronicity: Colorectal tumour and liver metastases 
On the international registry of liver metastasis from CRC, LiverMet Survey, a 51.7% of 
synchronicity has been recorded in January 2011 (table 1). This frequent sort of presentation, 
together with the expansion of the criteria of resectability and the laparoscopic approach for 
the colorectal and liver surgery, have created a new insight within the multidisciplinary teams.  
 
Sinc/Metac 
Number of 
patients 
1 year 3 year 5 year 10 year 
Sincronic 6112 90% 58% 39% 22% 
Metacronic 5724 90% 60% 43% 26% 
Table 1. LiverMet Survey, January 2011. Survival rates in 11836 patients after hepatectomy 
(with permission). 
As mentioned, colon resection can be done on the first stage, or a liver approach can be done 
first after a downstaging of the liver tumour/tumours. What should be done first depends on 
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the primary tumour (mainly in cases of rectal cancer that require an ultralow resection or are 
T3 or T4) and on the volume of liver parenchyma that needs to be removed. If the patient has 
been downstaged to resectability, the liver should be approached first (if possible) and the 
colorectal tumour should be operated 4 to 6 weeks later (Figure 4).  
 
Fig. 4. Large liver metastasis involving the three hepatic veins (upper pictures) in a 61 year 
old patient with rectal cancer. After 3 months of chemotherapy (lower pictures) the patient 
underwent left hepatectomy, segment (Sg) 1 and Sg 8 segmentectomies and right hepatic 
vein reconstruction. Six weeks later the rectal cancer was resected. 
5.5 Ante-situ, in-situ and ex-situ procedures: Extreme liver surgery  
Liver transplantation has brought with it advances in techniques that can be applied to 
nontransplant hepatic surgery. The lessons learned from reducing adult-sized livers for 
implantation in children, living related donor liver transplantation and split liver 
transplantation can all be applied in the nontransplant setting. Tumours that were 
considered unresectable with standard techniques can now be considered for resection 
using in-situ, ante-situ and ex vivo or bench liver surgery. In the last technique, the liver is 
completely removed from the patient and perfused with preservation solution. A bloodless 
transection of hepatic parenchyma can then be performed allowing complex reconstruction 
of hepatic veins or portal structures after which the liver is reimplanted in the patient. The 
ex vivo technique was first performed by Pichlmayr and colleagues in 1988 and has been 
applied sparingly in selected patients since then (Hemming et al. 2000). 
The common basis for in-situ, ante-situ and ex-situ resection is the total vascular exclusion 
(TVE) of the liver, and the perfusion of the organ by preservation hypothermic solution. 
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The principles are the same for the three techniques, which differ only in the extent to 
which liver is mobilized from its vascular connections, hylum and caval vein. Generally, a 
veno-venous bypass is used to avoid venous congestion during prolonged caval and 
portal crossclamping and a hypothermic preservation solution is instilled through the 
portal vein (Fortner et al. 1978). In a study population about liver resection under TVE, 
Azoulay et al. concluded that standard TVE of any duration with hypothermic perfusion 
of the liver, in this issue in-situ procedure, was associated with a better tolerance to 
ischemia. Furthermore, compared with TVE ≥ 60 minutes, it was associated with better 
post-operative liver and renal functions and lower morbidity (Azoulay et al. 2005). The 
main indications of the three techniques are tumours that involve vascular structures of 
the hylum, venous confluence or inferior vena cava (IVC), or are in close proximity to 
them. The technique can be used for benign, primary or metastatic tumours. The decision 
about what technique to use depends on the tumour location and its relationship with the 
three hepatic veins and caval vein. It is important to notice that the ex-situ technique is 
losing support due to its high morbidity and mortality. The location of the lesion or 
lesions in or near the suprahepatic IVC represents a true challenge due to the 
impossibility of using conventional resection techniques. Furthermore, optimal peri-
operative anaesthetic management is crucial in this setting, and the anaesthesia team 
should be familiar with the hepatic transplant procedure.  
The involvement of the inferior vena cava does not necessarily preclude resection (Figure 5). 
Liver resection with reconstruction of the IVC can be performed in selected cases. The resected 
IVC may then be replaced with an autogenous vein graft or a prosthetic material. The 
mortality rate of resection IVC is 4.5-25% and morbidity up to 40% (Azoulay et al. 2005). The 
increased risk associated with the procedure appears to be balanced by the possible benefits, 
particularly when the lack of alternative approaches is considered (Hemming et al. 2004).  
In conclusion, liver resections, due to the adoption of several advanced techniques, such as 
vascular exclusion, veno-venous bypass, hypothermic perfusion of the liver (in-situ, ante-
situ or ex-situ), have become more common and, when IVC is involved, resection of the vein 
is no longer considered a contraindication. 
 
Fig. 5. Huge liver metastasis in a 64 year old patient with colon cancer. First surgery was an 
extended right hepatectomy plus Sg 1 segmentectomy, after PVE of right and Sg 4 portal 
veins. A left hemicolectomy was performed 7 weeks later. 
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6. Repeat resections 
The first large series of liver resections for secondary tumours was reported in 1978 (Foster 
1978). By improvement in surgical techniques, peri-operative patient’s care and management 
of complications, the morbidity and mortality associated with liver resection were reduced. 
This has been a very important factor to increase the aggressiveness of the surgical approach.  
 
Fig. 6. LiverMet database, with permission. 
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Liver recurrence of CRC is common (Figure 6) but only 5-27% of the patients are candidates 
for potentially curative repeated hepatectomy. About 70% of recurrences will be observed 
within the first 12 months after resection and 92% will be apparent within 24 months 
(Langenhoff et al. 2009). In medically fit patients, repeat hepatectomy has emerged as a safe 
and effective procedure under the same criteria of selection of the first hepatectomy. 
Although the prognostic variables provide rough indicators of prognosis, they should not be 
used as absolute contraindications to surgery. The multidisciplinary team should plan the 
strategy individually. Each new re-hepatectomy needs a particular and specific evaluation: 
disease-free interval, number of metastases, quality of life, general health condition, 
resectable extrahepatic disease, assessment of residual liver volume, etc. by the 
multidisciplinary team (Figure 7). 
 
 
Fig. 7. A 63 year old patient with right hepatectomy plus Sg 4a resection; 24 months later a 
recurrence involving the only hepatic vein (left hepatic vein) appeared. Tumour was 
removed and the left hepatic vein was reimplanted in the caval vein using graft prosthesis 
(less than 60 minutes of total vascular exclusion). 
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The LiverMet Survey includes 12448 liver resections of which 14.5% are repeated 
hepatectomies (Figure 8, Table 2). Patients likely to benefit of this approach represent a 
small and highly selected group. Maybe, an accurate genetic, immunohistochemical and 
histological profile of the patient’s tumour will be able to conclude who will benefit from 
this aggressive treatment.          
 
Fig. 8. LiverMet Survey: number of hepatectomies. 
 
Repeat hepatectomies Patients % over initial resection 3-years SV 5-years SV 
LiverMetsurvey (2011) 1794 15 58 37 
Adam et al. (2003)  199 32 54 35 
Fernandez - Trigo et al. (1995) 170 No reported  28 
Petrowsky et al. (2002) 126 8 51 34 
Nordlinger et al. (1994) 116 6 33  
Ishiguro et al. (2006) 111 No reported 74 41 
Thelen et al. (2007) 94 12 55 38 
Yamamoto et al. (1999) 75 21 48 31 
Shaw et al. (2006) 66 9 68 44 
Adam et al. (1997)  64 26 60 41 
Yan, et al. (2007) 55 14  49 
Nishio et al. (2007) 54 10 53 46 
Table 2. Repeat hepatectomies series and survival rates. 
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Recurrence after repeat hepatectomy has been reported in 60–80% of patients (Smith & 
McCall 2009). A few have resectable disease limited to the liver and may be candidates for a 
third or even fourth hepatic resection. In our group there are two patients with five 
hepatectomies. Reports of large repeated hepatectomy series show that 9-30% of patients 
who underwent a second hepatectomy for colorectal liver metastases had a third resection 
(Fong et al 1999; Söreide et al. 2008; Yamamoto et al. 1999; Petrowsky et al. 2002) and 4% of 
them had a fourth resection (Adam et al. 2003; Yamamoto et al. 1999). The safety of multiple 
repeated hepatic resections has been demonstrated in recent reports, and long-term 
survivors have been documented (Adam et al. 2003; Nordlinger et al, 1994; Yamamoto et al. 
1999; Petroswsky et al. 2002). LiverMet Survey published the largest series (n = 251) of third 
hepatectomies for recurrent CRC liver metastases with a survival benefit of 29% at 5 years. 
Adam et al. published a large series of patients who underwent a third liver resection with 
zero mortality and a morbidity rate of 5%, not significantly different from those who have 
had only one or two liver resections. In addition, patients with a third liver resection had a 
survival benefit of 32–38% at 5 years (Adam et al. 2003; Yamamoto et al. 1999). Major 
hepatectomy is possible in a minority of these patients, who represent a small and highly 
selected group (Petrowsky et al. 2002). 
7. Inmunohistochemical markers based on tissue microarrays 
The ideal marker predictor of outcome should include the following characteristics: of low 
cost and easy measure, reproducibility across institutions, and measurable both before 
and after treatment. Most importantly, this factor would predict major differences in 
outcome that significantly impact treatment. A clinical example is K-ras status as a 
predictor of response to therapy with cetuximab, a monoclonal antibody against the 
EGFR. In a prospective randomized controlled trial, patients with advanced CRC were 
randomized to receive treatment with or without cetuximab. When stratified for K-ras 
status, patients with wild type K-ras tumours demonstrated a significant survival 
advantage compared to those with mutated K-ras tumours, who derived no benefit from 
the agent. Therefore, patients with mutated K-ras do not receive cetuximab therapy and 
are spared the toxicity associated with a treatment with no proven benefit. To date, there 
is no specific clinical risk score or biomarker that specifically prognosticates or guides 
therapy for patients with resectable CRC liver metastases to this degree. This marker may 
combine the immunohistochemical markers of cell proliferation and cell cycle control, p53 
and Ki67. 
Surface antigen CD133 is a cell membrane glycoprotein that is considered as a cell surface 
marker expressed in stem cells of hematopoietic immature cells, but not in mature blood 
cells. CD133 has also been shown to be a marker of immature neuronal stem cells (Karoui et 
al. 2006). Two antibodies, CD133/1 or AC133 and CD133/2 (AC141), recognize it. CD133+ 
cells in colon cancer are helpful markers for detection of tumour initiating cells (Karoui et al. 
2006) (Figure 9). 
CD44 is considered as a cell membrane marker or epithelial cell adhesion molecule 
(EpCAM). Its phenotype EpCAMhigh-CD44+ is becoming established as a good marker for 
immature stem cells of human colon mucosa in certain series (Ieta et al. 2008) (Figure 10).  
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Fig. 9. Immunohistochemical pathological study. Positive membrane staining for stem cell 
markers CD133, CS-130127, CD133 (32AT1672) in most cells of metastatic adenocarcinoma. 
Santa Cruz Biotechnology®, Inc (x100).  
 
 
Fig. 10. Immunohistochemical pathological study. Positive membrane staining for stem cell 
markers CD44, EpCAMhigh-CD44+ in most cells of metastatic adenocarcinoma. Santa Cruz 
Biotechnology®, Inc (x400).  
CD166 is considered as a marker for both cell membrane or epithelial cell adhesion molecule 
(EpCAM) and cytoplasm (Figure 11). It is a marker of mesenchymal stem cells whose role in 
carcinogenesis is not fully clear (Ieta et al. 2008). Its phenotype EpCAMhigh-CD166+ added to 
EpCAMhigh-CD44+ is starting to be considered as an additional marker of immature stem 
cells in human colon mucosa (Dalerba et al. 2007). 
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Fig. 11. Immunohistochemical pathological study. Positive membrane staining for stem cell 
markers CD166, 35264, CD166 LYO 1 mL EpCAMhigh-CD166+ in most cells of metastatic 
adenocarcinoma. Menarini Diagnostics® (x40).  
Borrego et al. (2010) analyzed, as did Kokudo et al. (2002), p53 expression. The 
immunohistochemical markers tested in their study (p53, Ki-67) were not poor prognostic 
factors, in agreement with Saw et al. (2002). By contrast, authors such as Tanaka et al. 2004 
reported that p53 or Ki-67 expression had a negative impact on survival. It should be 
noticed, however, that in Borrego-Estella et al.’s study survival was longer than 5 years in 
patients with high Ki-67 levels and in those with a high mitotic index (>10 mitosis/mm2), 
which is also another expression of the tumour proliferation index. However, no significant 
relationship was found between cell proliferation, as measured by Ki-67 and p53, whose 
changes express a loss of cell cycle control, and survival. 
For O’Brien et al. (2007), most CD133+ stem cells had a 200-fold greater oncogenic potential 
than CD133- cells for development of CRC. In addition, this subpopulation is able to 
maintain itself and to differentiate and become established again as a tumour when 
transplanted in certain solid organs of experimental animals. For Borrego-Estella et al. 
significant trends were found in their series with regard to membrane CD133 and CD166 
markers. According to O'Brien et al. and Ricci-Vitiani et al. 2007, in several CRC, CD44 was 
more determinant than CD133, because CD44 was expressed in tumour lines not expressing 
CD133.  
To compare the results of Borrego et al. with other groups is difficult since many authors 
(Fong et al. 1999; Pawlik et al. 2005) did not performed immunohistochemical studies. 
However, regarding immunohistochemical markers, more significant results were not 
achieved probably because the only technique performed was immunohistochemistry array, 
but not flow cytometry or other molecular biology techniques. 
Another interesting marker, microsatellite instability, is a measure of the inability of the 
DNA mismatch repair system to correct errors that occur during DNA replication. It is the 
alternative pathway to chromosomal instability with loss of heterozygosity in colorectal 
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carcinogenesis. Microsatellite instability has been suggested to be prognostic for survival 
and predictive for response to therapy in patients with colorectal cancer. 
In conclusion, many studies have analyzed pre-operative prognostic factors in patients 
undergoing liver resection for hepatic metastases from CRC in order to select patients for 
surgery. However, intraoperative and post-operative factors have been poorly analyzed. 
Future studies should establish post-operative prognostic factors through histological and 
immunohistochemical tests based on the tissue microarray technique.  
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